ROS1-Positive Non-Small Cell Lung Cancer

The ROS1-Positive Non-Small Cell Lung Cancer pipeline: 3 tracked drugs, 3 approved for this indication.

Coverage in progress. The assets here come from their companies' published pipelines. AssetMemo has not yet run its full census of every drug in development for ROS1-Positive Non-Small Cell Lung Cancer, so this list is not complete.

3 approved / phase 4

Compare the share prices of listed companies in ROS1-Positive Non-Small Cell Lung Cancer →

Market size not yet sourced. How markets are sized ↗

The ROS1-Positive Non-Small Cell Lung Cancer pipeline

← all assets